###begin article-title 0
###xml 150 159 150 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 270 281 270 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
###xml 306 315 306 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
Multiple sclerosis (MS) is a complex trait in which genes in the MHC class II region exert the single strongest effect on genetic susceptibility. The principal MHC class II haplotype that increases MS risk in individuals of Northern European descent are those that bear HLA-DRB1*15. However, several other HLA-DRB1 alleles have been positively and negatively associated with MS and each of the main allelotypes is composed of many sub-allelotypes with slightly different sequence composition. Given the role of this locus in antigen presentation it has been suggested that variations in the peptide binding site of the allele may underlie allelic variation in disease risk.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 104 113 104 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
In an investigation of 7,333 individuals from 1,352 MS families, we assessed the nucleotide sequence of HLA-DRB1 for any effects on disease susceptibility extending a recently published method of statistical analysis for family-based association studies to the particular challenges of hyper-variable genetic regions.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
We found that amino acid 60 of the HLA-DRB1 peptide sequence, which had previously been postulated based on structural features, is unlikely to play a major role. Instead, empirical evidence based on sequence information suggests that MS susceptibility arises primarily from amino acid 13.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 188 197 188 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
Identifying a single amino acid as a major risk factor provides major practical implications for risk and for the exploration of mechanisms, although the mechanism of amino acid 13 in the HLA-DRB1 sequence's involvement in MS as well as the identity of additional variants on MHC haplotypes that influence risk need to be uncovered.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system characterized by myelin loss, axonal pathology and progressive neurological dysfunction [1]. The aetiology of MS is unknown, but it is clear that both genetic and environmental components are important [2].
###end p 11
###begin p 12
###xml 136 150 136 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*1501 </italic>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL7R</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL2R</italic>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIF1B</italic>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
The only consistent genetic association with MS in Northern Europeans had been with extended MHC haplotypes especially those containing HLA-DRB1*1501 [3]. Recently, the interleukin 7 receptor (IL7R) interleukin 2 receptor (IL2R), ecotropic viral integration site 5 (EVI5) [4] and kinesin family member 1B (KIF1B) [5] genes have been shown to be additional MS susceptibility loci [3,6,7]. However, the MHC is the largest contributor to MS risk [3].
###end p 12
###begin p 13
###xml 91 135 91 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1*0102-DQB1*0602-DRB1*1501-DRB5*0101 </italic>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 403 404 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 461 473 461 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15 </italic>
###xml 557 569 557 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15 </italic>
###xml 573 585 573 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*17 </italic>
###xml 631 643 631 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*14 </italic>
###xml 647 659 647 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*11 </italic>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 716 736 716 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*10, DRB1*01</italic>
###xml 742 750 742 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*08 </italic>
###xml 764 776 764 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15 </italic>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
The association between MS and MHC class II has been fine mapped to the extended haplotype HLA-DQA1*0102-DQB1*0602-DRB1*1501-DRB5*0101 [8]. Intense linkage disequilibrium within the MHC has prevented the exact susceptibility locus from being identified. Analysis of the MHC region with a large number of markers as well as classical typing show evidence for the involvement of the class II region only [9,10]. The paradigm is more complex than one in which the HLA-DRB1*15 allele acts solely to increase MS risk. Our previous investigations have shown that HLA-DRB1*15 and HLA-DRB1*17 bearing haplotypes increase risk of MS, while HLA-DRB1*14 and HLA-DRB1*11 bearing haplotypes are protective [11,12]. Additionally, HLA-DRB1*10, DRB1*01, and DRB1*08 interact with HLA-DRB1*15 to influence disease risk [11,12].
###end p 13
###begin p 14
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 210 219 210 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 361 370 361 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 575 584 575 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1203 1210 1203 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 1211 1213 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1253 1266 1253 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*1501</italic>
###xml 1268 1273 1268 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1503</italic>
###xml 1275 1280 1275 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1701</italic>
###xml 1282 1287 1282 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0401</italic>
###xml 1289 1294 1289 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0801</italic>
###xml 1300 1306 1300 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0803 </italic>
###xml 1319 1334 1319 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*140101</italic>
###xml 1336 1343 1336 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*140102</italic>
###xml 1345 1352 1345 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*140103</italic>
###xml 1358 1364 1358 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1404 </italic>
###xml 1421 1430 1421 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1474 1483 1474 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1564 1573 1564 1573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1601 1612 1601 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*11</italic>
###xml 1614 1618 1614 1618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*10 </italic>
###xml 1622 1626 1622 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*01 </italic>
###xml 1627 1629 1627 1629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 721 729 <span type="species:ncbi:9606">patients</span>
MHC class II molecules present antigen to CD4+ T helper cells and are integral to successful maintenance of self tolerance by the immune system and the adaptive immune response to invading pathogens [13]. Each HLA-DRB1 allele forms, by the presence of defined amino acid anchors, a number of specific pockets comprising a peptide binding groove [14]. Different HLA-DRB1 alleles may thus have different binding affinities for disease-related peptides as determined by their protein sequence, subsequently influencing composition of T cell repertoires, ultimately resulting in HLA-DRB1 alleles having varying effects on disease risk. However, protein sequence analysis has failed to provide clarity. Class II alleles in MS patients are structurally no different to those in healthy controls [15]. While some studies have suggested that variable residues in the DR beta chain may determine MS susceptibility [16-18], others found no evidence that MS pathogenesis is mediated by allele overlapping antigen binding sites [19]. However, these studies were based on a relatively small number of individuals and, thus, may have been underpowered to detect any relevant effects [11,12]. More recently, Barcellos et al. [20], by aligning the protein sequences of HLA-DRB1*1501, *1503, *1701, *0401, *0801, and *0803 with that of HLA-DRB1*140101, *140102, *140103, and *1404 have suggested that the amino acid at position 60 of the HLA-DRB1 protein sequence determines the effect of a HLA-DRB1 allele on MS susceptibility. This model however does not take into account other HLA-DRB1 resistance alleles, notably HLA-DRB1*11, *10 and *01 [12].
###end p 14
###begin p 15
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 606 615 606 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
The HLA-DRB1 gene is unusual in that many loci in the coding sequence can have any one of the four nucleotides depending on the allelotype. Thus, empirical studies were difficult, first, because such variability requires large sample sizes, but - even more importantly - because most traditional statistical methods are limited to the more typical case of bi-allelic loci. We present here the largest systematic investigation to date and an extended more sensitive statistical approach, which, for the first time, will allow us to determine empirically whether or not the nucleotide or protein sequence of HLA-DRB1 can account for allelic susceptibility to MS.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Particpants
###end title 17
###begin p 18
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 4 16 <span type="species:ncbi:9606">participants</span>
All participants in the study were ascertained through the ongoing Canadian Collaborative Project on the Genetic Susceptibility to MS (CCPGSMS), for which the methodology has been previously described [21].
###end p 18
###begin title 19
Genotyping
###end title 19
###begin p 20
###xml 87 96 87 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 263 272 263 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 316 328 316 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*01 </italic>
###xml 331 342 331 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*10</italic>
Total genomic DNA, extracted from whole blood as part of the CCPGSMS, was used to type HLA-DRB1 alleles by an allele-specific PCR amplification method [22]. All genotypes were generated blind to pedigree structure and disease status of the individual. Initially, HLA-DRB1 alleles were classified into 10 categories, HLA-DRB1*01 to HLA-DRB1*10. Four of them were then subdivided, *05 into *11/12, *06 into *13/14, *02 into *15/16, and *03 into *17/18. Since then, these "two-digit" genotypes have been refined by adding two or four more digits. The first two digits describe the type, which corresponds to the serological antigen carried by an allelotype. The third and fourth digits are used to list the allele subtypes, numbers being assigned in the order in which the DNA sequences were determined. Alleles whose numbers differ in the first four digits must differ in one or more nucleotide substitutions that change the amino acid sequence of the encoded protein. Alleles that differ only by synonymous nucleotide substitutions within the coding sequence are distinguished by the use of the fifth and sixth digits.
###end p 20
###begin p 21
###xml 92 103 92 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*01</italic>
###xml 105 116 105 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04</italic>
###xml 118 129 118 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*07</italic>
###xml 131 142 131 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*08</italic>
###xml 144 155 144 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*09</italic>
###xml 157 168 157 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*10</italic>
###xml 170 181 170 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*11</italic>
###xml 183 194 183 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*12</italic>
###xml 196 207 196 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*13</italic>
###xml 209 220 209 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*14</italic>
###xml 222 233 222 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
###xml 235 246 235 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*16</italic>
###xml 248 259 248 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*17</italic>
###xml 265 276 265 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*18</italic>
###xml 283 292 283 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
In our population, 24 PCRs were carried out to amplify allelotypes corresponding to alleles HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*07, HLA-DRB1*08, HLA-DRB1*09, HLA-DRB1*10, HLA-DRB1*11, HLA-DRB1*12, HLA-DRB1*13, HLA-DRB1*14, HLA-DRB1*15, HLA-DRB1*16, HLA-DRB1*17, and HLA-DRB1*18. Each HLA-DRB1 genotype was scored twice by independent observers.
###end p 21
###begin title 22
Sequence Information
###end title 22
###begin p 23
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
HLA-DRB1 allele sequence information was obtained from the Immunogenetics database of the European Bioinformatics Institute [23], whose nucleotide and amino acid numbering scheme will be used here.
###end p 23
###begin title 24
Statistical Analysis
###end title 24
###begin p 25
###xml 207 216 207 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 220 229 220 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB2 </italic>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 191 196 <span type="species:ncbi:9606">human</span>
For terrestrial life forms, the number of alleles per single nucleotide polymorphism (SNP) is limited to five: A, C, G, T, and X (deletion), although only two alleles have been seen for most human SNPs. For HLA-DRB1 and HLA-DRB2 SNPs, however, up to 4 and 5 nucleotides, respectively, have been observed. As proven in [24], the informative data for each bi-allelic parental mating type (PMT) can be organized into three strata, with two informative filial constellations each:
###end p 25
###begin p 26
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mating</bold>
###xml 18 37 18 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Offspring Genotypes</bold>
Mating            Offspring Genotypes
###end p 26
###begin p 27
   A.A~A.C         A.A   A.C
###end p 27
###begin p 28
###xml 34 42 <span type="species:ncbi:9606">children</span>
   A.C~A.C         A.A   C.C (A.C children are non-informative)
###end p 28
###begin p 29
   A.C~C.C         A.C   C.C
###end p 29
###begin p 30
   ...
###end p 30
###begin p 31
   T.T~T.X         T.T   T.X
###end p 31
###begin p 32
###xml 34 42 <span type="species:ncbi:9606">children</span>
   T.X~T.X         T.T   X.X (T.X children are non-informative)
###end p 32
###begin p 33
   T.X~X.X         T.X   X.X
###end p 33
###begin p 34
With three alleles, only two constellations need to be considered:
###end p 34
###begin p 35
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mating</bold>
###xml 18 37 18 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Offspring Genotypes</bold>
Mating            Offspring Genotypes
###end p 35
###begin p 36
   A.A~C.G         A.C      A.G
###end p 36
###begin p 37
   A.C~A.G         A.A   A.C   A.G   C.G
###end p 37
###begin p 38
   ...
###end p 38
###begin p 39
   X.X~T.G         G.X      T.X
###end p 39
###begin p 40
   X.G~X.T         G.T   G.X   T.X   X.X
###end p 40
###begin p 41
With four or five alleles, each stratum contains four informative filial genotypes, e.g.:
###end p 41
###begin p 42
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mating</bold>
###xml 18 37 18 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Offspring Genotypes</bold>
Mating            Offspring Genotypes
###end p 42
###begin p 43
   A.C~G.T         A.G,   A.T   C.G   C.T
###end p 43
###begin p 44
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 56 64 <span type="species:ncbi:9606">children</span>
###xml 135 143 <span type="species:ncbi:9606">children</span>
To determine, whether a particular allele confers risk, children with this allele need to be 'paired' within the same PMT stratum with children having the same other allele. For bi-allelic PMTs, this leaves three informative mating types per combination of alleles, each with two informative filial genotypes [24]. For tri-allelic PMTs, two situations may arise. One homozygous parent, also yields only two filial genotypes, while two heterozygous parents, yield strata with four filial genotypes. For quad-allelic PMTs, both parents are necessarily heterozygous yielding, again, four possible filial genotypes.
###end p 44
###begin p 45
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 32 40 <span type="species:ncbi:9606">children</span>
###xml 752 760 <span type="species:ncbi:9606">children</span>
After excluding non-informative children, all filial genotypes within a PMT stratum have the same expectation under the null hypothesis. Thus, for the special case of bi-allelic parents, it has been suggested [25] that the sign/McNemar test for exact ties be applied [26], i.e. to count how often either of the genes were transmitted, irrespective of the PMT. Stratification [24] yields a test statistic based on counts representing independently observed events (cases born, rather than alleles transmitted, which are subject to identical genetical and environmental confounders). Here, the need for stratification is even more apparent than for bi-allelic parents [27-29], as there are, for instance, twice as many A alleles to be expected among the children of A.C~A.G parents than either C or G alleles.
###end p 45
###begin p 46
When developing a test suitable for multi-allelic loci, it is useful to note that the sign test can be written in the two equivalent forms given at the ends of the following equation:
###end p 46
###begin p 47

###end p 47
###begin p 48
As  and the "standardized residuals"  and  are symmetric, each follows asymptotically a standard Gaussian distribution, allowing the contributions from different PMT strata to be combined in an additive fashion.
###end p 48
###begin p 49
To test the effect of allele A, for instance, the following strata are informative:
###end p 49
###begin p 50
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mating</bold>
###xml 12 43 12 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Informative Offspring Genotypes</bold>
Mating      Informative Offspring Genotypes
###end p 50
###begin p 51
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.A~A.x:</underline>
   A.A~A.x: A.A   vs   A.x
###end p 51
###begin p 52
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~A.x:</underline>
   A.x~A.x: A.A   vs         x.x
###end p 52
###begin p 53
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~x.x:</underline>
   A.x~x.x:      A.x      vs   x.y
###end p 53
###begin p 54
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~y.y:</underline>
   A.x~y.y:      A.y      vs   x.y
###end p 54
###begin p 55
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~A.y:</underline>
   A.x~A.y: A.A   vs         x.y
###end p 55
###begin p 56
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~x.y:</underline>
   A.x~x.y:      (A.x + A.y)   vs   (x.x + x.y)
###end p 56
###begin p 57
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.y~x.y:</underline>
   A.y~x.y:      (A.x + A.y)   vs   (x.y + y.y)
###end p 57
###begin p 58
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~y.z:</underline>
   A.x~y.z:      (A.y + A.z)   vs   (x.y + x.z)
###end p 58
###begin p 59
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 16 24 <span type="species:ncbi:9606">children</span>
###xml 80 85 <span type="species:ncbi:12440">non-A</span>
###xml 296 301 <span type="species:ncbi:9606">child</span>
The informative children A.A in the A.x~A.x and A.x~A.y strata differ from the 'non-A' (x.x or x.y) counterparts by two alleles. As in [24], this will be accounted for by assigning twice the weight to these strata, rather than assuming that the effects of the two alleles transmitted to the same child are independently observed.
###end p 59
###begin p 60
With more than two alleles, several comparisons could be made within the A.x~A.y stratum, e.g.,
###end p 60
###begin p 61
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mating</bold>
###xml 12 43 12 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Informative Offspring Genotypes</bold>
Mating      Informative Offspring Genotypes
###end p 61
###begin p 62
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~A.y:</underline>
   A.x~A.y: (A.A + A.y)   vs   (A.x + x.y)
###end p 62
###begin p 63
###xml 3 11 3 11 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A.x~A.y:</underline>
   A.x~A.y: (A.A + A.x)   vs   (A.y + x.y)
###end p 63
###begin p 64
###xml 261 269 <span type="species:ncbi:9606">children</span>
###xml 295 303 <span type="species:ncbi:9606">children</span>
In both cases, the term to the left (A.A or A.x/A.y) would have more A alleles than the corresponding term on the right (A.x/A.y or x.y, respectively). Averaging across these comparisons yields the same term (A.x+A.y)/2 on both sides which, as the heterozygous children born to two heterozygous children in the biallelic case, can be ignored, resolving this seeming ambiguity. Again, stratification is essential for developing a sound statistical approach to deal with this complex situation.
###end p 64
###begin p 65
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">card </italic>
###xml 27 28 27 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 252 254 252 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w </italic>
From column card in Figure 1, the maximum number of informative strata for the influence of a given allele is 3 x 4 + 3 x 12 + 6 = 54 out of the 105. Of course, if a particular PMT is not observed, the corresponding strata need not be included. Column w gives the weight to be applied to this stratum's contribution based on the number of alleles differing.
###end p 65
###begin p 66
###xml 0 198 0 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Standardized residuals by parental mating type (PMT) with cardinality (card: number of combinations of non-A nucleotides x, y, and z per row) and weight (w: weight, depending on degree of dominance)</bold>
###xml 103 108 <span type="species:ncbi:12440">non-A</span>
Standardized residuals by parental mating type (PMT) with cardinality (card: number of combinations of non-A nucleotides x, y, and z per row) and weight (w: weight, depending on degree of dominance).
###end p 66
###begin p 67
This stratification now allows for different degrees of 'dominance' to be considered. An allele is "dominant" or "recessive", if having a single copy confers the same risk as having two copies or no copy, respectively.
###end p 67
###begin p 68
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 175 180 175 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A. A </sub>
###xml 182 183 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 183 192 183 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#172;A.&#172;A</sub>
###xml 74 82 <span type="species:ncbi:9606">children</span>
When both parents are heterozygous for the allele of interest, only those children are counted where both alleles are equal to or different from the allele of interest (n* = nA. A + nnotA.notA). Thus, among these strata, the effective sample size depends on the allele considered.
###end p 68
###begin p 69
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
Using the results of [30], the strata's contributions can be combined into an allele-specific test statistic by forming a single test statistic from the sum of the effect estimates and their variances, respectively, e.g.,
###end p 69
###begin p 70

###end p 70
###begin p 71
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 228 232 228 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic>. <italic>A</italic></sub>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 235 239 235 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic>. <italic>x</italic></sub>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 245 248 245 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic>.+</sub>
###xml 163 168 <span type="species:ncbi:12440">non-A</span>
where x is the subset of the 54 PMTs informative (relevant and not empty) for nucleotide A, while  and  states the number of subjects with a preponderance of A or non-A alleles, respectively within the stratum indicated (i.e., nA. A, nA. x, or nA.+, see above).
###end p 71
###begin p 72
From the above, nucleotide-specific test statistics can be obtained by performing the following steps:
###end p 72
###begin p 73
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
1) Select the PMTs where at least one parent is heterozygous for the nucleotide considered (Figure 1).
###end p 73
###begin p 74
###xml 111 119 <span type="species:ncbi:9606">children</span>
2) Among the strata where both parents are heterozygous for the nucleotide considered, eliminate the counts of children that are also heterozygous for this nucleotide.
###end p 74
###begin p 75
###xml 96 104 <span type="species:ncbi:9606">children</span>
###xml 141 149 <span type="species:ncbi:9606">children</span>
3) By number of parental copies of the nucleotide of interest (1, 2, or 3), count the number of children with more (1 or 2) vs the number of children with less (0 or 1, respectively) alleles of this nucleotide.
###end p 75
###begin p 76
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
4) Perform the stratified McNemar test [24] based on these six numbers and the weights assigned to each of the three categories of strata according to the degree of dominance to be considered (Figure 1).
###end p 76
###begin title 77
Software
###end title 77
###begin p 78
Statistical analyses were done using S-PLUS 8.0  and the muStat library (available from  and ). Surface and cartoon representations were produced using PyMOL . The program VOLUMES (R. Esnouf., unpublished data) was used with a 1.4 A radius probe to map the extent of the P4 pocket cavity.
###end p 78
###begin title 79
Results
###end title 79
###begin p 80
###xml 33 41 <span type="species:ncbi:9606">children</span>
###xml 103 111 <span type="species:ncbi:9606">children</span>
Of 7333 genotyped subjects, 3178 children (1773 affected and 1405 unaffected) from 1352 families (1-15 children per family) had complete familial allele-type and disease status information available.
###end p 80
###begin p 81
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 464 476 464 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 566 577 566 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*01</italic>
###xml 579 582 579 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15</italic>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*16 </italic>
###xml 624 636 624 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*09 </italic>
Sequence analysis identified 93 SNPs that suffice to characterize the differences between the 13 main allelic types of HLA-DRB1. As shown in Table 1, the relationship between nucleotides and allelic groups is complex. Thus, characterizing subjects by the 13 allelic groups (two-digit resolution) may not suffice to identify the genetic factors contributing to disease susceptibility (or resistance). For instance, for the second SNP (nucleotide position (N) 016), HLA-DRB1*04 (T) is uniquely different from all other groups (C), while the third SNP (N037) separates HLA-DRB1*01, *15, and *16 (A) from all other alleles (G). HLA-DRB1*09 is the only allelic group characterized by a single allele at each of the 93 SNPs - all other allelotypes have genetic variability, often with more than two alleles observed within each allelic group at a given SNP. The region between N256 and N308 is characterized by various allelotypes with three or four potential nucleotides per SNP.
###end p 81
###begin p 82
Nucleotides (N#: nucleotide number, #A: amino acid number) found in 94 HLA-DRB1 SNPs discriminating the 13 main two-digit allelic groups (rows).
###end p 82
###begin p 83
Note that many SNPs have more than two nucleotides and some SNPs have several nucleotides for the same allelic group. For instance, Nucleotide 257 can be either A or T within allelotype *12 and A, T, or G within allelotype *13. Given the high prevalence of the HLA-DRB1*15 (15) allele, the nucleotide found in this group of alleles was used as the reference, unless several nucleotides were found in the alleles constituting the HLA-DRB1*15 group.
###end p 83
###begin p 84
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
This would render current statistical analysis strategies, comparing one allelic group against all others, highly inefficient. To resolve this conundrum, we extended a recently developed statistical approach that allowed us to assess at each of the 93 loci the association (controlled for population admixture) with each individual nucleotide (A, C, G, T, and deletion). The test statistics for this analysis are shown in Table 2 (left side).
###end p 84
###begin p 85
Test statistics for specific alleles at any of the 93 SNPs increasing (positive) or decreasing (negative) the risk of MS.
###end p 85
###begin p 86
Left side: analysis of cases, right side: analysis of unaffected siblings.
###end p 86
###begin p 87
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 82 90 <span type="species:ncbi:9606">children</span>
Traditionally, family-based association studies utilize information from affected children only. With MS, however, the unaffected siblings of cases can be reasonably assumed to have similar genetic and environmental risk factors. Thus, one can analyze the siblings in the same fashion as the controls, after reversing the role of putative protective and risk alleles. If a nucleotide at a particular locus confers a risk, its absence should confer protection. The right side of Table 2 shows that the genetic constellations seen in the siblings, in fact, closely resemble the results seen in the cases, thereby validating the results.
###end p 87
###begin p 88
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 164 172 <span type="species:ncbi:9606">children</span>
###xml 254 262 <span type="species:ncbi:9606">children</span>
###xml 380 388 <span type="species:ncbi:9606">children</span>
To be asymptotically equivalent with the TDT [25], the stratified McNemar test [24], by default, assumes a co-dominant model, doubling the weight of the homozygous children born to two heterozygous parents. For dominant and recessive alleles, homozygous children (for the risk allele or the wild type, respectively) carry either no or the same risk, respectively, as heterozygous children, Thus, by assigning zero weight to some and equal weights to other strata, one can shift the power towards recessive and dominant models, respectively. The results under the dominant, but not the recessive model (data not shown) were similar to the results under the co-dominance model, suggesting that individual alleles contribute substantially to risk.
###end p 88
###begin p 89
Based on these results, candidate loci for MS risk are (N = nucleotide position, A = Amino acid position):
###end p 89
###begin p 90
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Position</bold>
###xml 20 33 20 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Nucleotide(s)</bold>
###xml 39 74 39 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Allelotype Carrying Risk Nucleotide</bold>
Position            Nucleotide(s)      Allelotype Carrying Risk Nucleotide
###end p 90
###begin p 91
###xml 12 23 12 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
N085:   T   HLA-DRB1*15
###end p 91
###begin p 92
###xml 23 37 23 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15/16</italic>
N124-126/A013:   AGG   HLA-DRB1*15/16
###end p 92
###begin p 93
###xml 17 34 17 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*10/15/16</italic>
N375/A096:   A   HLA-DRB1*10/15/16
###end p 93
###begin p 94
###xml 45 59 45 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15/16</italic>
N390, 485, 511, 585/A101-142:   A, T, A, A   HLA-DRB1*15/16
###end p 94
###begin p 95
###xml 31 43 31 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15 </italic>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Thus, the sequence variants of HLA-DRB1*15 that increase MS risk can be narrowed down to these regions (Figure 2). N085 is in the promoter region, A013 is part of the antigen presentation P4 pocket, while A133-142 are part of the CD4 binding region [29]. (The region from #33 (N196/A37) to #64 (N365/A93) has more variability than the 13 categories can explain.)
###end p 95
###begin p 96
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Position of candidate risk polymorphic residues in HLA-DRB1*1501</bold>
Position of candidate risk polymorphic residues in HLA-DRB1*1501. a. Cartoon representation of HLA-DRB1 (PDB ID 1BX2) in which the Calpha atoms of candidate risk polymorphic residues (Table 2) are represented as small spheres (green). The beta1 and beta2 domains are labeled. b. Surface and cartoon representation of HLA-DRB! viewed from above the binding groove. The three-dimensional arrangement of the P4 pocket is shown as a grey mesh. The Calpha atoms of the polymorphic residues 13 beta (green) at the base of the P4 pocket and residue 60 beta (orange) are represented as small spheres.
###end p 96
###begin title 97
Discussion
###end title 97
###begin p 98
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 239 247 239 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*14 </italic>
###xml 350 353 350 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*11</italic>
###xml 384 387 384 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*08</italic>
###xml 418 422 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*01 </italic>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*10 </italic>
###xml 449 452 449 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15</italic>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*14 </italic>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15 </italic>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 687 691 687 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*14 </italic>
Multiple sclerosis is unambiguously associated with the MHC class II region and this gene exerts the strongest genetic effect on the risk of developing the disease [3]. We have shown that A013 is the key amino acid in defining the risk of HLA-DRB1, yet no molecular or functional explanation can be given for the dominant-negative effects of *14 and *11, the complementary effects of *08, and the protective nature of *01 and *10 in the presence of *15. It has been speculated that poor engagement of the encephalitogenic peptide in the context of *14 acts to alter the immune response in a dominant-negative manner and thereby reduce the effect of *15 [20]. Another explanation is that *14 binds one or more peptides that can delete autoreactive T cells.
###end p 98
###begin p 99
###xml 92 101 92 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
In this study, we performed the first empirical investigation of the nucleotide sequence of HLA-DRB1 with respect to determining disease risk. The statistical analysis employed in this study differs fundamentally from previous analyses conducted in that it is based on the actual nucleotides at a SNP, rather than HLA allelotypes. In other words, it allows at each locus the cases (or controls) to be categorized differently according to the nucleotides observed. In principle, we might have done the same analysis based on individual sequence data, irrespective of the two- (four- or six-) digit allele categories. In fact, using individual sequence data would avoid the ambiguities which reduced the sample size to fewer than 300 for the SNPs between N196 and N372 (Table 2) due to some allelotypes having many different nucleotides at these loci.
###end p 99
###begin p 100
###xml 104 113 104 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
For amino acid 13, for instance, we count cases with unambiguous parental mating type for the following HLA-DRB1 allelotypes (see Table 3):
###end p 100
###begin p 101
###xml 1 37 1 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">numbers indicate HLA-DRB1 allelotype</italic>
(numbers indicate HLA-DRB1 allelotype)
###end p 101
###begin p 102
As the categories are refined or individual sequence data becomes available, ambiguous cases will become fewer or avoided altogether, respectively.
###end p 102
###begin p 103
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 650 651 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 651 656 651 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">P. P </sub>
###xml 658 659 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 659 664 659 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">P. Q </sub>
###xml 666 667 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 667 671 667 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Q. Q</sub>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 701 706 701 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">P. P </sub>
###xml 708 709 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 709 713 709 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Q. Q</sub>
###xml 378 386 <span type="species:ncbi:9606">children</span>
###xml 728 733 <span type="species:ncbi:42554">tetra</span>
As in the case of case-control studies [31], counting alleles transmitted to cases, as suggested by [25] in the widely used Transmission-Disequilibrium-Test (TDT) has recently been proven to result in a suboptimal analysis strategy even in the case of bi-allelic parents [24], because the TDT's variance estimate is based, in part, on the counts of non-informative heterozygous children born to two heterozygous parents. As with Student's t- vs. the Gauss' z-test (which are also asymptotically equivalent), this additional variance would need to be accounted for. The stratified McNemar test [24], in contrast, avoids this problem by replacing 2 x (nP. P + nP. Q + nQ. Q) in the denominator by 4 x (nP. P + nQ. Q). For tri- or tetra-allelic parents, stratification is even more important, because it also leads to novel analysis strategies.
###end p 103
###begin p 104
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 18 20 18 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 98 110 98 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*14 </italic>
###xml 175 189 175 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*1401 </italic>
###xml 220 233 220 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*1701</italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0401</italic>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0801 </italic>
###xml 252 258 252 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1501 </italic>
###xml 371 382 371 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
###xml 383 386 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15</italic>
###xml 388 399 388 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15</italic>
###xml 400 404 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*08 </italic>
###xml 408 420 408 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*14 </italic>
Barcellos et al. [20] have suggested that amino acid 60 accounts for the protective effect of the HLA-DRB1*14 allele, because this locus is close to the P4 binding pocket and HLA-DRB1*1401 encodes histidine (CAC), while HLA-DRB1*1701, *0401, *0801 and *1501 all encode tyrosine (TAC). Upon close inspection of the SNP profiles, however, the observed relationship between HLA-DRB1*15/*15, HLA-DRB1*15/*08 and HLA-DRB1*14 seems to be more complex.
###end p 104
###begin p 105
###xml 18 27 18 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 95 107 95 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*15 </italic>
Among the 4-digit HLA-DRB1 allelotypes, the majority of alleles code TAC for tyrosine, as does HLA-DRB1*15 (all 4-digit allelotypes).
###end p 105
###begin p 106
###xml 0 5 0 5 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Codon</bold>
###xml 22 34 22 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*14 </italic>
###xml 11 59 11 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Four digit <italic>HLA-DRB1*14 </italic>allelotype carrying codon</bold>
Codon      Four digit HLA-DRB1*14 allelotype carrying codon
###end p 106
###begin p 107
   TAC (14xx): 02,03,05,06,09,11,12,13,14,15,17,18,19,20,21,23,24,27,29,30,33,
###end p 107
###begin p 108
         36,37,40,41,42,43,44,45,36,47,51,52,56,57,59,63,65,67,76,77
###end p 108
###begin p 109
###xml 15 17 15 17 <underline xmlns:xlink="http://www.w3.org/1999/xlink">01</underline>
###xml 18 20 18 20 <underline xmlns:xlink="http://www.w3.org/1999/xlink">04</underline>
   CAC (14xx): 01,04,07,08,10,16,22,25,26,28,31,32,34,35,38,39,49,50,53,54,55,
###end p 109
###begin p 110
         58,60,61,62,68,69,70,71,72,73,74,75
###end p 110
###begin p 111
   TCC (14xx): 48,64
###end p 111
###begin p 112
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1401 </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*1404</italic>
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0101</italic>
###xml 397 402 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0103</italic>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0104</italic>
###xml 411 416 411 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0110</italic>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*0111</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*08 </italic>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*08 </italic>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
In the population of [32], 30% of the population were genotyped at the 4-digit level. Among them, 82% were *1401 and 9% were *1404. If one assumes that these 30% were representative and that the same proportion holds for our population, H at P60 could exert its "protective" effect in about 90% of all 14xx subjects. However, the purported disease risk increasing TAC codon is also seen in *0101, *0103, *0104, *0110, and *0111. Thus, if this amino acid should cause *08 to have its special role in *15/*08 heterozygous subjects, this effect should be seen with other alleles, yet this is not the case [11,12].
###end p 112
###begin p 113
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15 </italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*08 </italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*14 </italic>
For amino acid 13, instead, *15 (all K) is disjoint from both *08 (all G/glycine) and *14 (mostly S/serine)
###end p 113
###begin p 114
###xml 0 5 0 5 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Codon</bold>
###xml 11 20 11 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 11 45 11 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>HLA-DRB1 </italic>allelotype carrying codon</bold>
Codon      HLA-DRB1 allelotype carrying codon
###end p 114
###begin p 115
   AGG/K (15xx): (all)
###end p 115
###begin p 116
   GGT/G (08xx): (all)
###end p 116
###begin p 117
   TCT/S (14xx): 01,02,03,05,06,07,08,09,12,13,14,16,17,18,19,20,21,22,23,24,25,
###end p 117
###begin p 118
         26,27,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,51,
###end p 118
###begin p 119
         53,54,55,56,58,59,60,62,63,64,65,66,67,69,70,72,74,75,77
###end p 119
###begin p 120
   GGT/G (14xx): 04,11,15,28,29,30,50,52,61,68,71,73,76,
###end p 120
###begin p 121
   CAT/H (14xx): 10,31,57
###end p 121
###begin p 122
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 858 867 858 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
From this data, it seems unlikely that histidine at amino acid 60 contributes substantially to the protective effect of this haplotype. Instead, amino acid 13 emerges as a more likely explanation for a disease association gradient [32]. It is the only amino acid that shows sufficient variation to explain a hierarchy of disease associated alleles, raising the possibility that TCT/S is, in fact, associated with protection, while GTT/G is associated with increased risk. Being located right in the center of the P4 binding pocket, amino acid 13 is a residue that is potentially in contact with presented peptides [29,32]. Another interesting finding of this paper is the implication that the promoter region, may play an important role. This finding lends notion to the idea of regulatory variants contributing to MS risk. As we have previously shown [33], HLA-DRB1 (and therefore amino acid 13) cannot fully explain the MHC class II associated MS risk and these nearby variants remain to be uncovered.
###end p 122
###begin p 123
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*02 </italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*15 </italic>
###xml 364 368 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*16 </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
It has been argued that "low resolution allele grouping [...] maximize [s] statistical power" [20', p. 2821] when comparing one group against all others. When increasing the sample size comes at the expense of increasing within group variance, however, statistical power often suffers. Let us assume that group *02 had not been separated into *15 (3994 cases) and *16 (208) cases. Then, according to Table 4, 208 'G' cases would have been added to the 3,994 'T' cases to a total of 4202, but the size of the 'G' group would have been reduced from 10,674 to 10,466. Even though the number of informative trios would slightly increase (from 1139 to 1171, see Table 2), the test statistic would drop from 11.022 to 10.689. The proposed statistical test, in contrast, utilized the information obtained through high resolution allelotyping (or sequencing) to increase group sizes by combining allelotypes with the same nucleotide at a given locus.
###end p 123
###begin p 124
Variation of genotypes for the amino acids marked in Table 2.
###end p 124
###begin p 125
(Rare observations, such as TCC in only two out of 77 14xx subcategories are omitted)
###end p 125
###begin p 126
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 397 405 397 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in trans</italic>
###xml 429 435 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in cis</italic>
As we have demonstrated above, introducing the concept of stratification by parental mating type has not only quantitative advantages [24] over the original more simplistic approach, but also qualitatively different results for SNPs with more than two alleles in the population. As more data are collected, the proposed method could even be extended to address the difference between association (in trans) and protein function (in cis). To do so, one could categorize filial genotypes by pairs of amino acids, rather than nucleotides, so that differences in nucleotides coding for the same protein would be ignored. Of course, to ensure that genetic confounders are eliminated, parental mating types should still be defined based on the genetic code, rather than the amino acid for which it is coding. While this strategy is based on a large number of possible combinations between three-nucleotide parental mating types and combinations of filial amino acids, the number of combinations observed at each locus is likely to be substantially smaller.
###end p 126
###begin title 127
Conclusion
###end title 127
###begin p 128
In conclusion, an extended statistical approach allowed us to identify A013 at the center of the P4 pocket of HLA-DRB1 as a potentially important (although unlikely exclusive) risk factor for MS.
###end p 128
###begin title 129
Competing interests
###end title 129
###begin p 130
The authors declare that they have no competing interests.
###end p 130
###begin title 131
Authors' contributions
###end title 131
###begin p 132
KMW and GCE conceived and designed the experiments. SVR, RM, DAD, ADS and KMW performed the experiments. SVR, GCE and KMW analyzed the data and wrote the paper.
###end p 132
###begin title 133
Pre-publication history
###end title 133
###begin p 134
The pre-publication history for this paper can be accessed here:
###end p 134
###begin p 135

###end p 135
###begin title 136
Acknowledgements
###end title 136
###begin p 137
###xml 36 44 <span type="species:ncbi:9606">patients</span>
The authors would like to thank all patients who generously participated in this study and physicians participating in the CCPGSMS. Experiments performed for this investigation comply with current guidelines and ethics. This work was funded by the Multiple Sclerosis Society of Canada Scientific Research Foundation and the Multiple Sclerosis Society of the United Kingdom. SVR is funded by the Medical Research Council of the United Kingdom. The project was also supported in part by Grant Number UL1RR024143 from the U.S. National Center for Research Resources (NCRR). The funding bodies had no role in the design of this study, the collection, analysis, and interpretation of data, the writing of the manuscript and in the decision to submit the manuscript for publication.
###end p 137
###begin article-title 138
Multiple sclerosis
###end article-title 138
###begin article-title 139
Environmental factors and multiple sclerosis
###end article-title 139
###begin article-title 140
Genes for multiple sclerosis
###end article-title 140
###begin article-title 141
EVI5 is a risk gene for multiple sclerosis
###end article-title 141
###begin article-title 142
Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis
###end article-title 142
###begin article-title 143
Risk alleles for multiple sclerosis identified by a genomewide study
###end article-title 143
###begin article-title 144
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis
###end article-title 144
###begin article-title 145
The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele
###end article-title 145
###begin article-title 146
A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis
###end article-title 146
###begin article-title 147
Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium
###end article-title 147
###begin article-title 148
Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance
###end article-title 148
###begin article-title 149
The Inheritance of Resistance Alleles in Multiple Sclerosis
###end article-title 149
###begin article-title 150
The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules
###end article-title 150
###begin article-title 151
MHC class II proteins and disease: a structural perspective
###end article-title 151
###begin article-title 152
###xml 55 63 <span type="species:ncbi:9606">patients</span>
HLA-DR and -DQ allelic sequences in multiple sclerosis patients are identical to those found in the general population
###end article-title 152
###begin article-title 153
Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DR beta 1 chain in multiple sclerosis
###end article-title 153
###begin article-title 154
Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles
###end article-title 154
###begin article-title 155
###xml 79 87 <span type="species:ncbi:9606">patients</span>
The DRB1 Val86/Val86 genotype associates with multiple sclerosis in Australian patients
###end article-title 155
###begin article-title 156
Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2
###end article-title 156
###begin article-title 157
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis
###end article-title 157
###begin article-title 158
Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group
###end article-title 158
###begin article-title 159
HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
###end article-title 159
###begin article-title 160
IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex
###end article-title 160
###begin article-title 161
A statistically valid alternative to the TDT
###end article-title 161
###begin article-title 162
Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM)
###end article-title 162
###begin article-title 163
Versions of the sign test in the presence of ties
###end article-title 163
###begin article-title 164
The TDT is a Statistically Valid Test: Reply to Wittkowski and Liu
###end article-title 164
###begin article-title 165
Reply to Wittkowski and Liu (Beyond the TDT: rejoinder to Ewens and Spielman)
###end article-title 165
###begin article-title 166
Beyond the TDT: Rejoinder to Ewens and Spielman
###end article-title 166
###begin article-title 167
Friedman-type statistics and consistent multiple comparisons for unbalanced designs
###end article-title 167
###begin article-title 168
From genotypes to genes: Doubling the sample size
###end article-title 168
###begin article-title 169
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
###end article-title 169
###begin article-title 170
HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility
###end article-title 170

